Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE N/A. (2021–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Market Cap | $21831 | $8M | — | — | — |
| Enterprise Value | $10M | $17M | — | — | — |
| P/E Ratio → | -0.00 | — | — | — | — |
| P/S Ratio | 0.02 | 5.54 | — | — | — |
| P/B Ratio | — | — | — | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| EV / Revenue | — | 12.59 | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Gross Margin | -6.8% | -6.8% | -40.8% | -112.1% | -188.5% |
| Operating Margin | -3030.4% | -3030.4% | -1006.5% | -15332.1% | -13520.3% |
| Net Profit Margin | -4762.8% | -4762.8% | -1677.4% | -14942.5% | -12623.9% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| ROE | — | — | — | — | — |
| ROA | -358.3% | -358.3% | -113.1% | -56.6% | -36.7% |
| ROIC | — | — | — | — | — |
| ROCE | -3500.9% | -3500.9% | -100.0% | -62.7% | -42.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | -42.48 | -42.48 | -15.48 | -58.04 | -4.85 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Current Ratio | 1.28 | 1.28 | 0.17 | 4.72 | 7.79 |
| Quick Ratio | 1.28 | 1.28 | 0.17 | 4.72 | 7.79 |
| Cash Ratio | 0.51 | 0.51 | 0.03 | 4.14 | 7.11 |
| Asset Turnover | — | 0.11 | 0.14 | 0.00 | 0.00 |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | — | — | — | — |
| Shares Outstanding | — | $789338 | $465299 | $2M | $2M |
Imminent liquidity and solvency crisis
According to current market data, BSLK trades at a P/S multiple of 0.12, a figure that, based on reported figures, suggests the market has largely abandoned expectations for near-term commercial scaling and is instead pricing the entity as a distressed asset with minimal residual option value.
The extremely low P/S ratio relative to broader synthetic biology peers indicates that investors are discounting the company's ability to generate sustainable revenue from its protein expression platform. This valuation appears to reflect a market consensus that the current business model is failing to achieve the necessary commercial traction to justify a higher multiple.
As reported in financial statements, BSLK's gross margin has fluctuated significantly, reaching a negative 6.77% on a TTM basis, which suggests that the company's direct production costs remain fundamentally misaligned with the market pricing power of its bio-engineered silk and beauty ingredients.
The persistent inability to maintain positive gross margins implies that the company's fermentation-based manufacturing process is currently value-destructive at its existing scale. Investors should monitor whether management can achieve the necessary yield improvements to move beyond this structural hurdle, as current margins suggest a business model that cannot support its own cost of goods sold.
Based on recent SEC filings, BSLK's asset turnover ratio has remained negligible at 0.04, which, when compared to industry benchmarks, highlights a severe lack of operational efficiency and an inability to convert the company's specialized laboratory infrastructure into meaningful, recurring revenue streams.
The erratic nature of the company's cash conversion cycle and DSO metrics suggests that revenue recognition is heavily dependent on non-recurring project milestones rather than a steady flow of commercial orders. This lack of operational velocity indicates that the company's capital is tied up in unproductive assets that fail to generate a return on investment.
As evidenced by the company's reported figures, the current ratio of 0.69 as of 2025Q3 indicates a precarious liquidity position, leaving the firm with insufficient short-term assets to comfortably cover its immediate obligations without relying on external, potentially dilutive financing sources.
The company's reliance on a shrinking cash buffer to fund ongoing operating losses suggests that liquidity is rapidly deteriorating. This situation warrants further investigation into the company's ability to maintain its status as a going concern, as the current ratio provides little margin for error in the event of further operational delays.
Based on an analysis of the company's business model, the P/S ratio is the most commonly misapplied metric, as it obscures the underlying cash burn and the lack of a viable path to positive gross margins in the current fermentation-based manufacturing environment.
Investors often rely on revenue multiples to value high-growth tech firms, but for BSLK, this metric fails to account for the fact that every dollar of revenue currently costs more than a dollar to produce. A more appropriate focus would be on the unit economics of protein yield and the cash burn rate, which provide a clearer picture of the company's actual financial health.
Includes 30+ ratios · 4 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BSLK stock.
Bolt Projects Holdings, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Based on historical data, Bolt Projects Holdings, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Bolt Projects Holdings, Inc. has -6.8% gross margin and -3030.4% operating margin.